Updates in Cancer Immunotherapy and Toxicity Management Seminar

March 23- 24, 2018

Double Tree Hotel by Hilton
8181 Airport Blvd.
Houston, TX  77061

Time: 8 a.m.-4 p.m. Daily

Goal: To Improve Adverse Event Management & Application of Immunotherapy in Cancer Management

www.acecancercareinc.org
SEMINAR GOAL:
There has been a paradigm shift in the management of patients with advanced cancer from “one size fits all” to providing personalized therapy tailored to the molecular landscape of the tumor. However, in recent years, breakthrough discoveries of immune checkpoints and durable responses observed with immunotherapeutic agents has been more transformative and has led to regulatory approval of the several checkpoint inhibitors for specific indications.

Prompted by the success of these checkpoint inhibitors, increasing number of immunotherapeutic agents are being investigated across the tumor board, which presents unique challenges to the treating physician. As immunotherapy works by unleashing the suppressed immune system to attack tumor cells rather than attacking the tumor cells directly, immunotherapeutic agents differ significantly from chemotherapeutic agents and consequently pose monitoring and managing toxicity challenges for medical teams, community oncologists, emergency room physicians, etc.

Furthermore, with success being made with these drugs, more and more cancer patients are demanding these drugs as first line therapies for the management of their cancers.

This seminar seek to provide an avenue to bring updates on the application of immunotherapy in treatment of various cancers and the management of their accompanying toxicities to community providers who are interested in winning the fight against cancer

Educational Objectives
After attending the activity, participants should be able to

- Demonstrate an understating of developmental therapeutics, the pathophysiology and application of the immunotherapy drugs (knowledge, competence, performance)
- Become competent in use of biomarkers and monitoring of response to immunotherapy drugs (knowledge, competence)
- Identify and avoid contraindications to immunotherapy drugs (knowledge, competence, performance, patient outcomes)
- Assess the application of immunotherapy drugs in cancer management including in combination with cytotoxic drugs, targeted therapy and radiation therapy (knowledge, competence)
- Recognize and manage toxicities associated with the drugs early to avoid disastrous outcomes for patients (knowledge, competence, performance, patient outcomes)

TARGET AUDIENCE
- Physicians
- Fellows/Students
- Physician Assistants
- Pharmacists
- Advanced Practice Registered Nurses
- Research Coordinators/Researchers
- Registered Nurses

EDUCATIONAL METHODS
- Lectures
- Case Presentation Including Interactive Audience Participation
- Question and Answer Sessions
- Panel Discussions

ACCREDITATION AND CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Texas MD Anderson Cancer Center and the Ace Cancer Care, Inc. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PLANNING COMMITTEE

Chairman: Aung Naing, MD
Associate Professor
Investigational Cancer Therapeutics Department
The University of Texas MD Anderson Cancer Center

Co-Chair: Jianjun Gao, MD
Assistant Professor
Department of Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center

Co-Chair: Eucharia Iwuanyanwu, DHSC, PA-C, FAAPA
President, Ace Cancer Care, Inc.
Physician Assistant, Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center

Diane Barber, PhD, APRN, ANP-BC, AOCNP
Advanced Practice Nurse
Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center

Joan Lim, PharmD, BCSP
Clinical Pharmacy Specialist
Pharmacy Clinical Programs
The University of Texas MD Anderson Cancer Center

Kristi English, CHCP
Manager
CME/Conference Management
The University of Texas MD Anderson Cancer Center
### FACULTY LIST

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Department</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anne K. Brinkman, APRN</strong></td>
<td></td>
<td>Advanced Prac Registered Nurse</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Ahmed Elsayem, MD</strong></td>
<td>Professor</td>
<td>Emergency Medicine</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Jianjun Gao, MD</strong></td>
<td>Associate Professor</td>
<td>Urology</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Isabella C Glitza Oliva, MD, PhD</strong></td>
<td>Assistant Professor</td>
<td>Melanoma Medical Oncology</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Joud Hajjar, MD</strong></td>
<td>Assistant Professor</td>
<td>Immunology, Allergy &amp; Rheumatology</td>
<td>Baylor College of Medicine and Texas Children's Hospital</td>
</tr>
<tr>
<td><strong>Eucharia Iwuanyanwu, DHSc, PA-C</strong></td>
<td>Physician Assistant</td>
<td>Investigational Cancer Therapeutics</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Sang Taek Kim, MD, PhD</strong></td>
<td>Instructor</td>
<td>General Internal Medicine</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Altan Mehmet, MD</strong></td>
<td>Assistant Professor</td>
<td>Thoracic/Head &amp; Neck Medical Oncology</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Ethan Miller, MD</strong></td>
<td>Assistant Professor</td>
<td>GI Herpetology &amp; Nutrition</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Aung Naing, MD</strong></td>
<td>Professor</td>
<td>Investigational Cancer Therapeutics</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Loretta Nastoupil, MD</strong></td>
<td>Assistant Professor</td>
<td>Lymphom/Myeloma</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Shubham Pant, MBBS</strong></td>
<td>Associate Professor</td>
<td>Investigational Cancer Therapeutics</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Anish Patel, MD</strong></td>
<td>Assistant Professor</td>
<td>Dermatology</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Vicki Shannon, MD</strong></td>
<td>Professor</td>
<td>Pulmonary Medicine</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>George Simon, MD</strong></td>
<td>Professor</td>
<td>Thoracic/Head &amp; Neck Medical Oncology</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Neeto Somaiah, MD</strong></td>
<td>Assistant Professor</td>
<td>Sarcoma Medical Oncology</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Sudhaka Tummala, MD</strong></td>
<td>Professor</td>
<td>Neurology</td>
<td>MD Anderson Cancer Center</td>
</tr>
</tbody>
</table>
March 23, 2018

7:30-8:00 a.m. Breakfast

8:00-8:10 a.m. Introduction of Program and First Speaker

8:10-8:50 a.m. Immune System Review and Cancer Escape Mechanism
Joud Hajjar, MD

8:50-9:40 a.m. Immunotherapy and Management of Head & Neck Cancers: Updates
Altan Mehmet, MD

9:40-10:20 a.m. Advances in Immunotherapy: Sarcomas
Neeto Somaiah, MD

10:20-11:00 Advances in Immunotherapy and Melanoma Management
Isabella C Glitza Oliva, MD, PhD

11:00-11:10 a.m. Break

11:10-11:35 a.m. Biomarkers and Correlates of Clinical Response in Cancer Immunotherapy
Aung Naing, MD

11:35-12:00 p.m. Panel Discussion

12:00-12:50 p.m. Lunch

12:50-1:30: p.m. Immune based Therapies in Gastrointestinal Cancers (Colon & Pancreatic)
Shubham Pant, MBBS

1:30-2:10 p.m. Lymphoma and Immunotherapy: Better Outcomes
Loretta Nastoupil, MD

2:10-2:55 p.m. Advances in Immunotherapy in Bladder and Renal Cancers
Jianjun Gao, MD

2:55-3:35 p.m. Endocrine Toxicities
Anne K. Brinkman, APRN

3:35-4:00 p.m. Panel Discussion
7:30-8:00 a.m.  Breakfast

8:00-8:10 a.m.  Introduction of Program and First Speaker

8:10-9:00 a.m.  Dermatological Toxicity: What to Expect & Management
    Anish Patel, MD

9:00-9:50 a.m.  Recognizing and Managing Gastrointestinal Toxicities
    (Ileitis, Colitis, Hepatitis, Pancreatitis)
    Ethan Miller, MD

9:50-10:00 a.m.  Break

9:50-10:50 a.m.  Immunotherapy and Lung Cancer Management: Updates
    George Simon, MD

10:50-11:30 a.m.  Immunotherapy Pulmonary Toxicity and Management
    Vicki Shannon, MD

11:30-12:00 p.m.  Panel Discussion

12:00-12:50 p.m.  Lunch

12:50-1:30 p.m.  Autoimmune Diseases: Contraindications to Immunotherapy
    Sang Taek Kim, MD, PhD

1:30-2:00 p.m.  Education for the Patient on Immunotherapy
    Eucharia Iwuanyanwu, DHSc, PA-C

2:00-2:45 p.m.  Neurotoxicity of Immunotherapy and Management
    Sudhaka Tummala, MD

2:45-3:30 p.m.  Immunotherapy Adverse Event:
    A Visit with the Emergency Room Physician
    Ahmed Elsayem, MD

3:30:4:00 p.m.  Panel Discussion